Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James D Neaton

Showing results (1-10 of 171) with videos related to

Pageof 18
Sort By:
JAMA|September 19, 2008
The Multiple Risk Factor Intervention Trial (MRFIT)--importance then and nowJeremiah Stamler, James D Neaton
Current Opinion in HIV and AIDS|April 18, 2009
Earlier initiation of antiretroviral therapy in treatment-naïve patients: implications of results of treatment interruption trialsJames D Neaton, Birgit Grund
Annals of Internal Medicine|April 16, 2003
When to start therapy for HIV infection: a swinging pendulum in search of dataH Clifford Lane, James D Neaton
Nature Medicine|April 9, 2008
Getting personal about treating HIVJames D Neaton, H Clifford Lane
Circulation|March 23, 2016
Letter by Kuller and Neaton Regarding Article, "Association of Race With Mortality and Cardiovascular Events in a Large Cohort of US Veterans"Lewis H Kuller, James D Neaton
JAMA|April 7, 2005
Diuretics are color blindJames D Neaton, Lewis H Kuller
Journal of Clinical Periodontology|August 11, 2006
From observational studies to randomized trials: asking the right question at the right timeJames D Neaton, Andrew S Mugglin
Clinical Trials (London, England)|March 20, 2018
How to construct an optimal interim report: What the data monitoring committee does and doesn't need to knowJames D Neaton, Birgit Grund, Deborah Wentworth
Current Opinion in HIV and AIDS|October 28, 2010
Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010James D Neaton, Jacqueline Neuhaus, Sean Emery
The Journal of Infectious Diseases|February 15, 2001
ReplySean Emery, H. Clifford Lane, James D. Neaton
Pageof 18

Showing results (1-10 of 171) with videos related to

Sort By:
Pageof 18
JAMA|September 19, 2008
The Multiple Risk Factor Intervention Trial (MRFIT)--importance then and nowJeremiah Stamler, James D Neaton
Current Opinion in HIV and AIDS|April 18, 2009
Earlier initiation of antiretroviral therapy in treatment-naïve patients: implications of results of treatment interruption trialsJames D Neaton, Birgit Grund
Annals of Internal Medicine|April 16, 2003
When to start therapy for HIV infection: a swinging pendulum in search of dataH Clifford Lane, James D Neaton
Nature Medicine|April 9, 2008
Getting personal about treating HIVJames D Neaton, H Clifford Lane
Circulation|March 23, 2016
Letter by Kuller and Neaton Regarding Article, "Association of Race With Mortality and Cardiovascular Events in a Large Cohort of US Veterans"Lewis H Kuller, James D Neaton
JAMA|April 7, 2005
Diuretics are color blindJames D Neaton, Lewis H Kuller
Journal of Clinical Periodontology|August 11, 2006
From observational studies to randomized trials: asking the right question at the right timeJames D Neaton, Andrew S Mugglin
Clinical Trials (London, England)|March 20, 2018
How to construct an optimal interim report: What the data monitoring committee does and doesn't need to knowJames D Neaton, Birgit Grund, Deborah Wentworth
Current Opinion in HIV and AIDS|October 28, 2010
Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010James D Neaton, Jacqueline Neuhaus, Sean Emery
The Journal of Infectious Diseases|February 15, 2001
ReplySean Emery, H. Clifford Lane, James D. Neaton
Pageof 18